Evidence map›Paper›PMID 37121104›Full record

ArticleMultiple sclerosis and related disorders2023

Vascular disease risk factors in multiple sclerosis: Effect on metabolism and brain volumes.

Manoj K Sammi, Allison Fryman, Eric Baker, Brendan Moloney, Katherine Powers, Randy West, Frank Bittner, Michael Lane, Kayla Martin, Yuliya Pepelyayeva and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Multiple sclerosis and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Manoj K SammiAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA. Electronic address: sammi@ohsu.edu.
Allison FrymanDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA; Department of Veterans Affairs MS Center of Excellence-West, Portland, OR, USA.
Eric BakerAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA.
Brendan MoloneyAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA.
Katherine PowersAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA.
Randy WestAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA.
Frank BittnerDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA.
Michael LaneDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA; Department of Veterans Affairs MS Center of Excellence-West, Portland, OR, USA.
Kayla MartinDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA; Department of Veterans Affairs MS Center of Excellence-West, Portland, OR, USA.
Yuliya PepelyayevaDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA.
Valerie C AndersonAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA.
William D RooneyAdvanced Imaging Research Center, Oregon Health & Science University, Portland, OR, USA.
Vijayshree YadavDepartment of Neurology, Oregon Health & Science University, Portland, OR, USA; Department of Veterans Affairs MS Center of Excellence-West, Portland, OR, USA. Electronic address: yadavv@ohsu.edu.
Oregon Health & Science University · US

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
A High-Performance Computing System for Advanced ImagingS10OD018224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ROONEY, WILLIAM D · 2014 to 2014
$222k
Vascular Disease Risk Factors and MS Progression: A Study of Brain MetabolismI01RX001636 · VA · PORTLAND VA MEDICAL CENTER · PI YADAV, VIJAYSHREE · 2015 to 2021
–
CSRD VA I01 CX001955NCATS NIH HHS UL1 TR002369NIH HHS S10 OD018224RRD VA I01 RX001636
6 · The paper itself

Abstract

backgroundVascular disease risk factors (VDRF) such as hypertension, hyperlipidemia, obesity, diabetes and heart disease likely play a role in disease progression in people with multiple sclerosis (PwMS) (Marrie, Rudick et al. 2010). Studies exploring the mechanistic connection between vascular disease and MS disease progression are scant. We hypothesized that phosphate energy metabolism impairment in PwMS with VDRFs (VDRF+) will be greater compared to PwMS without VDRFs (VDRF-) and is related to increased brain atrophy in VDRF+. To test this hypothesis, we planned to study the differences in the high energy phosphate (HEP) metabolites in cerebral gray matter as assessed by

methodsGroup differences in high energy phosphate metabolites were assessed from a volume of interest in the occipital region using linear mixed models. Brain parenchymal and white matter lesion volumes were determined from MR anatomic images. We present here the cross-sectional analysis of the baseline data collected as part of a longitudinal 3 yearlong study where we obtained baseline and subsequent 6-monthly clinical and laboratory data and annual 7T MRI volumetric and

resultsComplete MRI data were available for 29 VDRF+, age 56.3 (6.8) years [mean (SD)] (83% female), and 23 VDRF-, age 52.5 (7.5) years (57% female) individuals with MS. The mean value of normalized adenosine triphosphate (ATP) (calculated as the ratio of ATP to total phosphate signal in a voxel) was decreased by 4.5% (p < .05) in VDRF+ compared to VDRF- MS group. White matter lesion (WML) volume fraction in VDRF+ individuals {0.007 (0.007)} was more than doubled compared to VDRF- participants {0.003 (0.006), p= .02}.

conclusionsWe found significantly lower brain ATP and higher inorganic phosphate (Pi) in those PwMS with VDRFs compared to those without. ATP depletion may reflect mitochondrial dysfunction. Ongoing longitudinal data analysis from this study, not presented here, will evaluate the relationship of phosphate metabolites, brain atrophy and disease progression in PwMS with and without vascular disease.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveVascular DiseasesAtrophyBrainCross-Sectional StudiesDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPhosphatesQuality of LifeRisk FactorsPhosphatesComorbiditiesMagnetic resonance imagingMitochondrial functionMultiple sclerosisVascular risk

Identifiers

PMID37121104
PMCPMC10560072
OpenAlexW4362467114

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.